GlassScriptPhysician profile
Kan Huang
NPI 1598095622
$8,255.98
in general payments reported to CMS, 2019-2025
55 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $216 · 2021: $633 · 2022: $564 · 2023: $2,796 · 2024: $1,300 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,218 · Consulting Fee: $1,388 · Travel and Lodging: $504 · Education: $51.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.93 |
| Consulting Fee | $1,387.50 |
| Travel and Lodging | $503.90 |
| Education | $51.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,255.76 | 2022-2025 | Enhertu, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $695.42 | 2019-2025 | |
| Janssen Biotech, INC. | $544.38 | 2019-2025 | Darzalex, Carvykti, Tecvayli |
| Merck Sharp & Dohme LLC | $421.69 | 2019-2025 | Keytruda |
| Incyte Corporation | $400.14 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $340.17 | 2019-2025 | Polivy, Columvi, Tecentriq |
| Pfizer INC. | $318.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $243.07 | 2019-2025 | Krazati, Opdivo |
| Regeneron Healthcare Solutions, INC. | $241.80 | 2021-2025 | Libtayo |
| Amgen INC. | $225.92 | 2019 | |
| Genzyme Corporation | $208.70 | 2019-2025 | |
| Celgene Corporation | $202.49 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $160.19 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Abbvie INC. | $155.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.52 | 2023-2025 | Alunbrig, Fruzaqla, Iclusig |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $98.72 | 2019-2025 | Jaypirca, Verzenio |
| Aurobindo Pharma USA, INC. | $94.85 | 2019 | |
| Emd Serono, INC. | $91.45 | 2023-2025 | Bavencio |
| G1 Therapeutics, INC. | $88.93 | 2022-2023 | Cosela |
| Mirati Therapeutics, INC. | $88.41 | 2023-2024 | Krazati |
| Eisai INC. | $88.32 | 2019-2024 | |
| Stemline Therapeutics INC. | $77.86 | 2023-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $76.38 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Jazz Pharmaceuticals INC. | $74.47 | 2021-2025 | |
| Array Biopharma INC | $74.25 | 2020-2025 | Lorbrena, Braftovi, Mektovi |
| Gilead Sciences, INC. | $71.48 | 2021-2025 | Trodelvy |
| Tesaro, INC. | $70.47 | 2019 | |
| Exelixis INC. | $67.12 | 2019-2024 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $58.68 | 2024-2025 | Onivyde, Somatuline Depot |
| Clovis Oncology, INC. | $58.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.16 | 2023-2025 | Ojjaara, Jemperli |
| Tempus Ai, INC | $39.79 | 2024-2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $39.65 | 2020-2022 | |
| Genmab U.S., INC. | $34.66 | 2024-2025 | Tivdak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.27 | 2021-2025 | |
| Adc Therapeutics America, INC. | $33.78 | 2024-2025 | |
| Taiho Oncology, INC. | $31.48 | 2023-2024 | |
| Caris Mpi, INC. | $28.16 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $26.65 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.85 | 2025 | Monoferric |
| Servier Pharmaceuticals LLC | $18.37 | 2023 | |
| Myovant Sciences INC. | $16.93 | 2021 | |
| Verastem, INC. | $16.54 | 2019 | |
| Karyopharm Therapeutics INC. | $16.38 | 2021 | |
| Tg Therapeutics, INC. | $15.47 | 2021 | |
| Astellas Pharma US INC | $14.78 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.34 | 2025 | |
| Beigene USA, INC. | $14.11 | 2023 | Brukinsa |
| Kyowa Kirin, INC. | $14.07 | 2023 | Poteligeo |
| Blue Earth Diagnostics | $13.09 | 2019 | |
| Seagen INC. | $12.95 | 2023 | Adcetris |
| Sobi, INC | $12.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.34 | 2019 | |
| Aveo Pharmaceuticals, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kan Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.